Treatment strategies for DMD have been done using genetic4–9, pharmacological10,11, or cellular12–16 approaches aimed at restoring dystrophin-associated glycoprotein (DAG) complex, reversing sarcolemmal fragility, and abating muscular dystrophy. This evidence concerns the gene DMD and Duchenne muscular dystrophy.